

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-22. (Canceled)

23. (Currently Amended) A method for detecting prostate cancer in a patient comprising:

(a) obtaining a biological sample from the patient;

(b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein said oligonucleotides primers are specific for a DNA molecule comprising a sequence selected from the group consisting of nucleotide residues 1341-2694 of SEQ ID NO:110 and complements of nucleotide residues 1341-2694 of SEQ ID NO:110; and

(c) detecting in the sample an expressed polynucleotide DNA sequence that amplifies in the presence of the oligonucleotide primers thereby detecting prostate cancer, wherein the biological sample is selected from the group consisting of blood and semen.

24. (Currently Amended) The method of claim 23, wherein the oligonucleotide primers comprises at least about 10 contiguous nucleotides of nucleotide residues 1341-2694 of SEQ ID NO:110, or complements of nucleotide residues 1341-2694 of SEQ ID NO:110.

25.-34. (Canceled)

35. (Currently Amended) A method for detecting the presence of an expressed DNA polynucleotide sequence molecule comprising of SEQ ID NO: 110 in a biological sample, the method comprising:

(a) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein the oligonucleotide primers are specific for nucleotide

check  
new  
re-  
for spec  
MA

residues 1341-2694 of SEQ ID NO:110 and complements of nucleotide residues 1341-2694 of SEQ ID NO:110; and

*complete*

(b) detecting in the sample an expressed DNA-polynucleotide sequence that amplifies in the presence of the oligonucleotide primers, wherein the biological sample is selected from the group consisting of blood and semen.

*MJ*

36. (Currently Amended) The method of claim 35, wherein the oligonucleotide primers comprise at least about 10 contiguous nucleotides of nucleotide residues 1341-2694 of SEQ ID NO:110, and complements of nucleotide residues 1341-2694 of SEQ ID NO:110.

*complete*

37.-46. (Canceled)